SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently trending as investors focus on the anticipated mid-year commercial launch of Veppanu, the first FDA-approved PROTAC therapy, which the community views as a potential blockbuster asset. Despite strong fundamentals and profitability, the stock is seeing high volatility and significant short interest, leading to intense debate among retail investors about the potential for a short squeeze or strategic acquisition.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending as the market reacts to shifting geopolitical tensions in the Strait of Hormuz, with investors closely watching for the upcoming Valaris acquisition and potential earnings catalysts. The community is actively debating the stock's long-term potential as a beneficiary of offshore drilling demand versus short-term price volatility fueled by ongoing energy sector speculation.

Honeywell International, Inc. is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It operates through the following business segments: Aerospace Technologies, Industrial Automation, Building Automation, Energy and Sustainability Solutions, and Corporate and All Other. The company was founded by Albert M. Butz in 1906 and is headquartered in Charlotte, NC.

Honeywell International Inc

Honeywell is trending due to anticipation surrounding its upcoming earnings report and the strategic spin-off of its Advanced Materials unit, Solstice Advanced Materials. Investors are closely monitoring these developments as community sentiment remains focused on the potential value unlock from the company's multi-part breakup and its ongoing efforts to optimize operations across its core aerospace and automation segments.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. The firm’s products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits, and embedded graphics. The company was founded by Wallace C. Kou in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is experiencing significant momentum and investor interest, driven by its critical role in AI-focused enterprise storage and the successful rollout of advanced controller solutions. The community is actively discussing the stock's strong technical breakout, institutional accumulation, and the strategic positioning of its high-performance SSD and memory controller technology within the booming AI data center infrastructure market.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is experiencing a massive surge following a robust earnings report that showcased significant revenue growth and positive guidance, fueling strong community sentiment regarding the company's long-term potential in AI-driven medical imaging. While some traders are capitalizing on the explosive upward momentum, others are actively debating whether this represents a sustained shift or another cyclical pump-and-dump susceptible to dilution and institutional selling.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to the announcement of a $3.6 billion acquisition of AI customer service firm Fin, aimed at bolstering its Agentforce platform. The community is actively debating the stock's significant recent sell-off, with many investors pointing to its low forward valuation, record share buybacks, and expanding AI-driven recurring revenue as reasons for a potential reversal despite ongoing concerns about the broader software sector.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure as investors debate whether the current multi-year lows represent a long-term accumulation opportunity or if the project is losing relevance in an increasingly competitive blockchain sector. The community remains deeply divided, with some highlighting strong fundamental utility while others express frustration over sustained price depreciation and a lack of recovery momentum compared to broader crypto markets.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining momentum as investors react to encouraging subcutaneous BRIUMVI data for myasthenia gravis, fueling optimism about expanding the drug's addressable market beyond multiple sclerosis. The community is actively debating the company's valuation, with many long-term shareholders anticipating a potential buyout and highlighting the asset as a strategic fit for larger pharmaceutical companies looking to capture significant market share.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is gaining significant traction as investors bet on the company's progress toward commercializing portable microreactors, specifically following a strategic partnership with Supermicro to power AI data centers. The community is actively debating the stock's speculative growth potential against its lack of current revenue, with many traders focusing on the company's NRC licensing progress and its recent acquisition of logistics assets to verticalize its supply chain.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance continues to draw intense investor scrutiny as the market weighs the pending $110 billion merger with Warner Bros. Discovery against ongoing regulatory hurdles and recent antitrust lawsuits from several U.S. states. While shareholders express frustration over stagnant price action and the dilution associated with the deal, the community remains actively divided between those betting on long-term synergies and those deeply skeptical of management's ability to navigate current regulatory and debt headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adaptive Biotechnologies Business Separation May Unlock Greater Value

William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.read more...

Adaptive Biotechnologies Prices Upsized $300 Mln Sr. Notes Offering

(RTTNews) - Adaptive Biotechnologies Corporation (ADPT) on Wednesday said it has priced an upsized private offering of $300 million of 0% convertible senior notes due 2031...

John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday

Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Buster's and Adaptive Biotechnologies saw after-hours trading dips.read more...

Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?

Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

JPMorgan Chase & Co. Lowers Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $19.00

JPMorgan Chase & Co. cut their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an 'overweight' rating for the company in a research note on Wednesday...

Adaptive Biotechnologies (NASDAQ:ADPT) Given Buy Rating at Guggenheim

Guggenheim restated a "buy" rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday...

BTIG Research Reiterates Buy Rating for Adaptive Biotechnologies (NASDAQ:ADPT)

BTIG Research reaffirmed a 'buy' rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday...

Adaptive Biotechnologies (NASDAQ:ADPT) Announces Earnings Results

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of...

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Adaptive Biotechnologies Q1 Earnings Call Highlights

Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed accelerating momentum in measurable residual disease (MRD) testing, alongside continued...

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

Adaptive Biotechnologies Corp

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ADPTAdaptive Biotechnologies Corp

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADPT News